|
|
|
| home > ebr > summer 2004 > fully automated storage creates an open source for genetic epidemiology |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| Over the last two decades, genetic epidemiology has demonstrated its ability to identify single genes of large effect through family studies. Knowledge of the human genome sequence and its major variants should now permit investigators to identify genes, individually of small effect, that modify the complex interaction between genetic and environmental factors. It is this interaction that is believed to lead to common diseases. These considerations led the UK Medical Research Council (MRC) to identify genetic epidemiology as a strategically important area for translating genome sequence into human health benefits. In October 2000 it announced awards to permit investigators to collect 40,000 DNA samples from patient cohorts and case-control series, and to deposit them in a national DNA bank so as to enable third party access. The awards encompassed diseases listed in Table 1. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients
Based in Szczecin, this facility extends Nemera’s manufacturing
capabilities and will bring more drug delivery device solutions to
patients. Following the dynamic growth of
the drug delivery devices market, as a world leader, Nemera is thrilled
to extend its manufacturing capabilities in Poland.
More info >> |
|
 |
White Papers |
 |
|
The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing
GE Healthcare Life Sciences
For the past several years, the biopharma industry has been buffeted by
dynamic market conditions that are rapidly reshaping manufacturing
requirements. These factors include:
• The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model
• Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint
• The emergence of biosimilars and continued evolution of healthcare
reform, which will increasingly pressure drug pricing and require
greater cost discipline
• Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures
• Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >> |
|
|
.jpg)
